Xiaoyan Liu
Xiaoyan Liu
Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan 250012, P.R. of China
Biography
PhD in Leiden University Medical Center. My PhD thesis is about sunitinib, which used as first-line treatment for metastatic renal cell carcinoma (mRCC). However, the interindividual variance of sunitinib is large, with only 35% of mRCC patients response to this drug. The objective of my PhD research is to explore some SNPs for the association with sunitinib outcome in mRCC patients.